Travere Therapeutics Inc TVTX

US Biotechnology

$59.44 ▼ -1.95% ($-1.18)

Open $60.89

Prev Close $60.62

Day Range $59.05 – $60.89

52W Range $22.06 – $68.73

Market Cap $5.60B

Beta 1.07

EPS (TTM) $-0.50

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2003-07-23
Shares Out.	92,990,000
Website	travere.com/ ↗
Phone	18889697879
Employees	497
Revenue	$169.6M
Gross Profit	$167.4M
Net Income	-$34.8M
Free Cash Flow	$92.5M
Total Assets	$799.4M
Total Liabilities	$774.8M
Equity	$24.5M

About Travere Therapeutics Inc

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Travere Therapeutics Inc is a publicly traded company under the ticker symbol TVTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.